In yesterday’s Wall Street session, Evelo Biosciences Inc (NASDAQ:EVLO) shares traded at $0.43, up 37.23% from the previous session.
2 analysts cover Evelo Biosciences Inc (NASDAQ:EVLO), according to research data. The consensus rating among analysts is ‘Underweight’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $10.00, we find $10.00. Given the previous closing price of $0.31, this indicates a potential upside of 3125.81 percent. EVLO stock price is now -88.65% away from the 50-day moving average and -93.53% away from the 200-day moving average. The market capitalization of the company currently stands at $8.01M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $10.00 as their price target over the next twelve months.
With the price target maintained at $12, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Evelo Biosciences Inc (NASDAQ: EVLO).
In other news, McHale Duncan, Chief Medical Officer sold 6,854 shares of the company’s stock on Nov 02. The stock was sold for $2,262 at an average price of $0.33. Upon completion of the transaction, the Chief Medical Officer now directly owns 13,587 shares in the company, valued at $5842.41. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 02, CSO, President of R&D Bodmer Mark sold 6,854 shares of the business’s stock. A total of $2,262 was realized by selling the stock at an average price of $0.33. This leaves the insider owning 22,270 shares of the company worth $9576.1. Insiders disposed of 176,963 shares of company stock worth roughly $76094.09 over the past 1 year. A total of 50.61% of the company’s stock is owned by insiders.
On Friday morning Evelo Biosciences Inc (NASDAQ: EVLO) stock kicked off with the opening price of $0.3280. During the past 12 months, Evelo Biosciences Inc has had a low of $0.30 and a high of $48.00. The fifty day moving average price for EVLO is $3.6436 and a two-hundred day moving average price translates $6.4649 for the stock.
The latest earnings results from Evelo Biosciences Inc (NASDAQ: EVLO) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$3.78, missing analysts’ expectations of -$3.3 by -0.48. This compares to -$8.07 EPS in the same period last year. The company reported revenue of $19.57 million for the quarter, compared to $29.59 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -33.84 percent.
Evelo Biosciences Inc(EVLO) Company Profile
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
